Preview
Filed 12 Ma 25 P1:51
Chris Daniel - District Clerk
Harris Coun!
CURRICULUM VITAE ED101) 016898557
By: Charlie Tezeno
JERRY J. TOMASOVIC, M.D.
FRA IS RR IIHR HATES IO HIRT RTE ATTA TIA BRIER IIIT TR TITER TTR TITRA IE
ADDRESS: Road Runner Research Management, LLC
525 Oak Centre Drive, Suite 400
San Antonio, Texas 78258
EDUCATION AND TRAINING:
Undergraduate: University of Chicago, Chicago, IL, B.S., 1962
Medical School: University of Chicago, Chicago, IL, M.D., 1965
Rotating Internship - USAF Hospital Andrews, Andrews AFB, 1965-66
Pediatric Residency - US Naval Hospital Bethesda, Bethesda, 1966-68
Pediatric Neurology Fellowship - University of Colorado Medical Center,
ae Denver, CO, 1972-75
BOARD CERTIFICATIONS/LICENSURES:
Diplomate American Board of Pediatrics, 1970
Diplomate American Board of Psychiatry and Neurology with Special
Competence in Child Neurology, 1978
Association of Professional Sleep Societies, July 1989
Professional Licensure: Texas, February 1985 No. G7730
PRACTICE EXPERIENCE:
Owner, President of Road Runner Research Management, LLC, Jan. 2006-Present.
Owner, President, and Medical Director, Road Runner Research, Ltd., October 2005-
Present.
Owner, President, and Medical Director, Texas Association of Pediatric Neurology, Inc.,
June 2000- Present.
Medical Director, Spasticity Clinic, S.W. Texas Methodist Hospital, San Antonio, TX,
1997-Present.
Consultant, Pediatric Neurology, Movement Disorders Clinic, Warm Springs Hospital,
San Antonio, TX, 1997-2002,
Private Practice, Adult and Child Neurology, San Antonio, TX, 1985-Present.
Medical Director, Sleep Diagnostics Services Inc, San Antonio, TX, 1992-2009
One Oak Hills Place, 1901 Babcock Rd, suite 201, SA, TX 78229
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE
Neurological Program Consultant, Laurel Ridge Hospital, San Antonio, TX, 1992-2000
Co-Medical Director, Sleep/Wake Disorders Center of South Texas, San Antonio, TX.
1988-1992,
Teaching clinic monthly at Wilford Hall USAF Medical Center, Lackland AFB, TX,
1988-1993.
Co-Medical Director, Electroneurodiagnostic Laboratory of San Antonio, TX, 1987-1994
Co-Unit Medical Director, Neuropsychiatric Inpatient Unit, Laurel Ridge Hospital, San
Antonio, TX, March 1988-1991,
Co-Medical Director, Neurobehavioral Evaluation Team (NET), San Antonio, TX, 1989-
1991,
Associate Professor of Pediatrics, University of Texas Health Science Center at San
Antonio, TX, 1985-1986
Chairman, Department of Neurology and Program Director, USAF Neurology Residency
Program, Wilford Hall USAF Medical Center, Lackland AFB, TX, 1979-1985.
Staff Child Neurologist, Department of Pediatrics, Wilford Hall USAF Medical Center,
Lackland AFB, TX, 1977-1979.
Child Neurologist, Assistant Chairman, Department of Pediatrics, USAF Hospital Travis,
Travis AFB, CA, 1975-1977.
Staff Pediatrician, USAF Hospital Wiesbaden, Germany, 1968-1972 (Assistant Chief,
1969-1972)
ACADEMIC APPOINTMENTS:
Clinical Professor of Neurology, University of Texas Health Science Center at San
Antonio, TX, September 2003-Present.
Clinical Professor of Pediatrics, University of Texas Health Science Center at San
Antonio, TX, September 1994-Sept 2003.
Clinical Associate Professor of Pediatrics, University of Texas Health Science Center at
San Antonio, TX, 1978-1985 and 1986-1994.
Clinical Associate Professor of Neurology, University of Texas Health Science Center at
San Antonio, TX, 1980-1985.
Associate Scientist (Adjunct), Southwest Foundation for Biomedical Research, San
Antonio, TX, 1986-1989.
Assistant Clinical Professor of Pediatrics, University of California, Davis, CA, 1975-1977.
Clinical Associate Professor of Neurology, Uniformed Service of the Health Sciences,
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE
School of Medicine, Bethesda, MD, 1980-1985.
MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS:
Member, American Academy of Neurology, 1974-present.
Member, Child Neurology Society, 1974-present.
Member, American Sleep Disorders Association, 1986-present.
Member, Bexar County Medical Society, 1985-present.
Member, Texas Medical Association, 1985-present.
Member, American Medical Association, 1989-present.
Member, American Epilepsy Society, 1977-1999.
Member, American Academy of Child & Adolescent Psychiatry, 1992-1999.
Member, San Antonio Pediatric Society, 1985-1990.
PROFESSIONAL HONORS/EXECUTIVE POSITIONS HELD:
Legion of Merit, United States Air Force, 1977-1985.
Professional and Community Advisory Council, Epilepsy Foundation of America, San
Antonio, TX, 1992-Present.
Chairman, Department of Neurology and Program Director, USAF Neurology Residency
Program, Wilford Hall USAF Medical Center, Lackland AFB, TX, 1979-1985.
Military Consultant to the Surgeon General for Adult and Child Neurology, 1980-1985.
Chairman, Committee on Neurology and Government Services, American Academy of
Neurology, 1983-1984.
President, Uniformed Services of Neurologists, 1984-1985.
Fellow, American Academy of Neurology, 1985.
Voted Best Doctors in America 2011-Present.
Texas Super Doctors, a special section in Texas Monthly, featuring 5% of Texas doctors,
2008-Present
One of America’s Most Compassionate Doctors, Patients’ Choice Rated and Awarded by
Patients, 2008-Present
PUBLISHED ARTICLES, SPEECHES, and LECTURES:
a. J.J. Tomasovic, T. Sabo: Improvement of Intractable Headache in Adolescents
Females after Craniocervical Injections of BTX-A (Allergan), Headache, Vol 43,
No.5, May2003, pp.579-580
J.J. Tomasovic, D.E. Solomon, D.H, Solomon: Chapter 11: Neurologic
Consultation. Clinical Anesthesia Practice, W.B. Saunders Company,
Philadelphia, PA, 1994, pp. 152-169.
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE
J.J. Tomasovic, Neurobiology of Aggression, proceeding from 9th National
Conference of Child Psychiatry, sponsored by Mexican Association for Child
Psychiatry, Guanajuato, Mexico, November 1992.
L.A. Stone, J.J. Tomasovic, T.A. Martin, M.B. Zuelzer, E.C. Gooze: Episodic
Dyscontrol, Disinhibition, Explosive Personality, and Intermittent Explosive
Disorders, proceedings from 39th Annual Meeting of American Academy of
Child and Adolescent Psychiatry, Washington, D.C., October 1992,
W.White, J. Mumma, J.J. Tomasovic: Congenital Oculomotor Nerve Palsy,
Cerebellar Hypoplasia, and Facial Capillary Hemangioma, American Journal of
Ophthalmology, Vol. 113, No. 5, May 15, 1992, pp. 497-500.
J.J. Tomasovic: Sleep Disorders, The Treatment of Psychiatric Disorders,
Revised for the DSM3R, Wm. H. Reid Ed., Chapter 22, 1989, pp. 296-310.
M. Brunsvold, J.J. Tomasovic, D. Ruemping: The Measured Effects of Phenytoin
Withdrawal on Gingival Hyperplasia in Children, Journal of Dentistry for
Children, November-December 1985, pp. 417-421.
h. B. Ryan, R. Bell, D. Null, J.J. Tomasovic, Dryer: Study of the Effects of Sleep
State Upon Anterior Cerebral Artery Flow Characteristics in Neonates. Abstract
presented in San Francisco, CA, 1982.
S.A, McGuire, N. Ackerman, J.J. Tomasovic: Hereditary Continuous Muscle
Fiber Activity. Arch Neurology, Vol. 41, April 1984.
S.A. McGuire, J.J. Tomasovic, E.A. Stevens: Improvement With Corticotropin of
Relapsing CNS Sarcoidosis During Prednisone Therapy. Military Medicine, Vol.
149, No. 5, May 1983.
R.A. DeLemos, D. Null, J.J. Tomasovic: The Role of Postnatal Factors in the
Pathogenesis of Subependymal and Intracranial Hemorrhage in the Premature
Infant. Syllabus of the Perinatal Intracranial Hemorrhage Conference
Washington, D.C., December 11-13, 1980.
JL. Liston, J.J. Tomasovic: Early Diagnosis and Management of Cerebritis in a
Child. Pediatrics, 1980, 65:484.
J.G. Marks, Jr., J.J. Tomasovic: Linear Nevus Sebaceous Syndrome. Journal of
the American Academy of Dermatology, Vol. 2, No.1, 1980, pp. 31-32.
R.A. DeLemos, J.J. Tomasovie: Effects of Positive Pressure Ventilation on
Cerebral Blood flow in the Newborn Infant. Symposium on the respiratory
system. Clinics in Perinatology, Vol. 5, No. 2, September 1978, pp. 395-409.
J.J, Tomasovic, G. Nellhaus, P.G. Moe: The Bobble-Head Doll Syndrome: An
Early Sign of Hydrocephalus. Two new cases and a review of the literature.
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE
Developmental Med and Child Neurology, Vol. 17, No. 6, December 1975, pp.
777-183.
10. REVIEWS:
a, Distal Jugular Venous Cannulation During Extracorporeal Membrane
Oxygenation in Neonates by Ernesto S. Gangitan, M.D., et. al. for Pediatrics,
October 1991.
Neonatal Neurology by Gerald M. Fenichel, P. 270, New York Churchill-
Livingston, 1980 for Arch Neurology, vol. 38, June 1981.
1h. HOSPITAL PRIVILEGES AND PROFESSIONAL STAFF, SAN
ANTONIO, TEXAS
a Active Staff:
S.W. Texas Methodist Children’s Hospital
North Central Baptist Hospital
Santa Rosa Children’s Hospital
Laurel Ridge Hospital
Consulting Staff:
Baptist Memorial Hospital System
Covenant Hospital
Mission Road Developmental Center
Northeast Methodist Hospital
Santa Rosa Hospital System
Sid Peterson Memorial Hospital, Kerrville, TX.
Vencor Hospital
Warm Springs Rehabilitation Hospital
West Texas Rehabilitation Center, San Angelo, TX
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE
CLINICAL RESEARCH EXPERIENCE:
Principal Investigator: Protocol for a Multicenter Long Term Study to Maximize
Migraine Relief with 311C90
Sub-Investigator: A Multicenter, Double-Blind, Randomized Placebo-Controlled.
Parallel Group Study of the Efficacy and Safety of Oral xxxxxx in Adolescent Subjects
Ages 12-17 Years with Acute Migraine
Principal Investigator: A Multicenter, Randomized, Open-Label, Comparative Study of
the Safety, Toleration and Efficacy of Oral xxxxxx FOR long Term Treatment of Subjects
with Acute Migraine
Principal Investigator: Safety and Efficacy of xxxxx in the Treatment of Pediatric
Patients with Partial Seizures
Principal Investigator: An Open-Label Extension Study of xxxx in the Treatment of
Pediatric Patients with Partial Seizures
Principal Investigator: A Double-Blind, Placebo-Controlied, Parallel Group Study to
Evaluate Three Dose Levels (Smg, 10mg, 20 mg) of xxxxxxxxNasal Spray in the Acute
Treatment of a Single Migraine Attack in Adolescent Migraineurs (12-17 years of age)
Sub-Investigator: An open-Label Study to Evaluate the Long Term Efficacy, Safety and
Tolerability of xxxxxxx Nasal Spray xxxxxxx in an Adolescent Migraine Population
Principal Investigator: Almirall 638-CNS-0059-015 - A Randomized,
Doubie-Blind, Placebo-Controlled Study of Oral almotriptan in the Acute
Treatment of Migraine in Adolescents
Principal Investigator: UCB Pharma RPCE97L2601 - A Multicenter,
Open Label, Long-Tterm, Follow-Up Study of the Safety and Efficacy of
levetiracetam in Children with Epilepsy
Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled
Evaluation of xxxxx (311090, XXXX) Efficacy at Early Time Points in the Acute
Treatment of Migraine Headaches, Efficacy in Recurrence of Migraine Headaches
Principal Investigator: A Double-Blind, Randomized Trial of Two Dose Ranges of xxxxxxxx
and Placebo in the Prophylactic Treatment of Migraine
Sub-Investigator: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial and an
Open Label Long-term Tolerability Trial of x200xx (xxxxxx) for the Acute Treatment of Migraine
Headaches in Adolescent Subjects
Sub-hnvestigator: "An Open-Label Study to Evaluate the Long Term Efficacy, Safety and
Tolerability of (GR43175C) in an Adolescent Migraine Population,"
Principal Investigator: MerckMAX564: A Multicenter, Double-Blind, Randomized, the
Efficacy and Tolerability of Rizatriptan 10 mg Tablet for the Treatment of Menstrual
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE
Migraines
Principal Investigator: Merck MK-0462-074-00 /MAX573: A Randomized,
Double-Blind, Placebo —Controlled Study to Evaluate the Elimination of Migraine
Associated Nausea in Migraine Patients Treated with rizatriptan orally
Disintegrating Tablet (ODT)
Primary Investigator; Cephalon Eclipse MOO-190: A Compliance Packaging and Safety
Assessment of Two Packaging Formats and Dosing Regimens of Gabitril in Subjects with
Partial-Onset Seizures. January 2001-September2001.
Primary Investigator: Shire Pharmaceutical SLI381-305: An Open-Label, Multicenter
Study to Assess Tolerability, Effectiveness and Quality of Life Associated with The Use of
Adderall XR in Children with Attention Deficit Hyperactivity Disorder in a Community
Practice Setting. August 2001 -January 2002.
Sub-Investigator: UCB Pharma RPCE9862502/N159: Evaluation of the Efficacy and
Tolerability of Levetiracetam Add-on Treatment in Refractory Pediatric Patients with Partial-
Onset Seizures: A 28-week Double-Blind, Placebo-Controlled Multicenter Trial.
August 2001-March 2003.
Sub-Investigator: Allergan Botox 01 (Investigator Initiated, Pilot Study) B -Botulinum
Toxin A for Migraine Prophylaxis in an Adolescent Population.
September 2001-March 2003.
Primary Investigator: GlaxoSmithKline SUM40301: An Open-Label Evaluation of Patient
Satisfaction with Imitrex tablets 100 mg, Administered at the First Sign of Pain for up to
Three Migraine in Patients Who are Not Satisfied with Their Current Triptan Therapy.
November 2001-June 2003
Primary Investigator: GlaxoSmithKline LAM40013: A Multicenter Open-Label Conversion
of Valproate Monotherapy to Lamotrigine Monotherapy in Patients with Epilepsy.
January 2002-March 2003.
Primary Investigator: Abbott M02-552: A Randomized, Double-Blind, Parallel Group,
Multicenter Study of the Safety and Efficacy of Depakote in Treatment of Partial Seizures in.
Children. Nov. 2003
Principal Investigator: Shire SPD433-401 Cabatrol SPEQT (Safety, Preference, Effectiveness,
and Tolerability) Trial, A Multicenter, Open Label, Phase IV Study to Assess the Tolerability,
Safety and Effectiveness of Switching from Carbamazepine Immediate Release and Liquid
Formulations to Carbatrol Extended Release Capsules in Epilepsy Subjects Within a Community
Based Population. June 2003
Sub-Investigator; Glaxo Wellcome LAM40097: A Multi-Center, Double-Bind, Randomized,
Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subject
with Primary Generalized Tonic-Clonic Seizures. March 2000-2004
Sub-Investigator: UCB Pharma RPCE97L2601/N157: A Multicenter, Open-Label,
Long-Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam (ucb L059) in
Children with Epilepsy. August 2001-May 21,2004
JERRY J. FOMASOVIC, MD - CURRICULUM VITAE
Primary Investigator: GlaxoSmith Kline RM2004/00208/00: A Randomized, Double-Blind,
Parallel Group, Placebo-Controlled, Single Attack Evaluation of the Efficacy and Tolerability of
Trexima (sumatriptan 85 mg/naproxen sodium 500 mg) tablets versus Placebo When
Administered During the Mild Pain Phase of a Migraine. December 2004
Sub- Investigator: OrthoMcNeil CAPSS-122: A Comparison of the Efficacy and Safety
of topiramate Versus Placebo for the Prophylaxis of Migraine in Pediatric Subjects.
Completed March 2004.
Primary Investigator: Ortho McNeil Protocol 638-CNS-0059-015: A Randomized, Double-
Blind, Placebo-Controlled Study of Oral almotriptan 6.25 mg, 12.5 mg and 25 mg in the Acute
Treatment of Migraine in Adolescents. April 2004
Primary Investigator: Novartis CRTI47B US36 & Extension Portion of Study: A
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy
and Safety of Trileptal as Prophylactic Therapy in Outpatients Suffering from Migraine
Headaches. Completed May 2004
Primary Investigator: GlaxoSmithKline CXA20008: A Multicenter, Randomized, Double-
Blind, Single-Dose, Parallel Group Pilot Study to Assess the Safety and Efficacy of the Cox-2
Inhibitor versus Placebo and Naproxen Sodium versus Placebo in the Treatment of Acute Migraine.
2003-May 2004
Primary Investigator: GlaxoSmithKline SUM30047: A Randomized, Double Blind, Placebo-
Controlled, Paralle] Group, Single Attack Study to Evaluate the Onset of Efficacy of a New
Formulation of sumatriptan Tablets in the Acute Treatment of Migraine. 2003-2004
Primary Investigator: Astra Zeneca D1221C0005: A Multicenter, Double-Blind, Randomized,
Placebo Controlled, 2way Crossover Study with a Single-Blind Placebo-challenge to Evaluate the
Efficacy and Safety of zolmitriptan Smg Nasal Spray in the treatment of Acute Migraine Headache
in Adolescents . 2004
Primary Investigator: GlaxoSmithKline LAM40097: A Multicenter, Double-Blind,
Randomized, Placebo-Controlled, Parallel Group Evaluation of lamotrigine Adjunctive
Therapy in Subject with Primary Generalized Tonic-Clonic Seizures. 2004
Primary Investigator: UCB Pharma RPCE97L.2601: A Multicenter, Open-Label, Long-Term,
Follow-Up Study of the Safety and Efficacy of levetiracetam in Children with Epilepsy. 2004.
Primary Investigator: Astra Zeneca D1221C0005: A Multicenter, Double-Blind, Randomized,
Placebo Controlled, 2way Crossover Study with a Single-Blind Placebo-Challenge to Evaluate the
Efficacy and Safety of zolmitriptan Smg Nasal Spray in the Treatment of Acute Migraine Headache
in Adolescents. 2004
Primary Investigator: Protocol 065: A Multicenter, Double-Blind, Randomized,
Parallel. Placebo-Controlled study to examine the Efficacy of rizatriptan 10 mg Tablet
administered early during a Migraine Attack while the Pain is Mild. April 2005
Primary Investigator: Protocol 066-00/MAX550: A Multicenter, Double-Blind,
Randomized. Parallel, Placebo-Controlled Study to Examine the Efficacy of rizatriptan
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE
10mg Tablet administered Early during a Migraine Attack While the Pain is Mild.
Primary Investigator: MT400-302: A Double-Blind, Multicenter, Randomized,
Placebo-Controlled study to evaluate the Safety and Efficacy of the Combination of
sumatriptan succinate and naproxen sodium in the Acute Treatment of Migraine
Headaches. 2005
Primary Investigator: GSK Lam40124: An Assessment of Behavioral Changes Associated with
jamotrigine and levetiracetam in Patients with Epilepsy. June 2003
Primary Investigator: Almirall 638-CNS-0059-015: A Randomized, Double-Blind Placebo-
Controlled Study of Oral almotriptan in the Acute Treatment of Migraine in Adolescents.
Principal Investigator: Cephalon 3027: A Randomized, Double-Blind, Placebo-
Controlled, Parallel Group Study to Assess the Efficacy and Safety of Provigil Treatment
in Children and Adolescents with Excessive Sleepiness Associated Narcolepsy. 2005
Principal Investigator: Abbott M02-488: The Safety and Efficacy of divalproex
sodium Extended-Release Tablets in Migraine Prophylaxis in Adolescents. 2006
Principal Investigator: Abbott M02-554: Extension Study to Above Protocol M02-488
2006
Principal Investigator: Abbott M04-714: An Open Label Multicenter Study of Long-
Term Safety of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in
Children, 2006
Principal Investigator: Ortho-McNeil CAPSS-316: Efficacy and Safety of Axert versus
Placebo for the Acute Treatment of Migraine Headaches.
Principal Investigator: Cephalon 3028: A Randomized, Double-Blind, Placebo-
Controlled, Parallel Group Study to Assess the Efficacy and Safety of Provigil Treatment
in Children and Adolescents with Excessive Sleepiness Associated With Obstructive
Sleep Apnea/Hypopnea Syndrome. 2005
Principal Investigator: Schwarz Trial Number SP754: A Multicenter, Double-Blind,
Randomized, Placebo-Controlled, Paralle! Group Trial to Investigate the Efficacy and
Safety of SPM927 (400 AND 600mg/DAY) as Adjunctive Therapy in Subjects with
Partial Seizures with or without Secondary Generalization. 2005
Principal Investigator: GlaxoSmithKlineTRX 103632: A Randomized, Double-Blind,
Multicenter, Placebo-Controlled, Cross-Over Study to Determine the Consistency of
Response for Trexima™ (sumatriptan 85mg/naproxen sodium 500mg) Administered
During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks, 2005
Primary Investigator: Merck 074-00/MAX573: A Randomized, Double-Blind,
Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in
Migraine Treated with rizatriptan Orally Disintegrating Tablet (ODT). 2005
Principal Investigator: Schwarz Trial Number SP756: An Open-Label Extension Trial
to Determine Safety and Efficacy of Long-Term Oral SPM 927 in Patients with Partial
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE
Seizures. 2005
Principal Investigator: OrthoMeNeil CAPSS 334 Efficacy of AXERT® (almotriptan
malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of
Preventive Therapy with TOPAMAX® (topiramate). 2005
Principal Investigator: Cephalon 3029 - Extension Study to Protocols 3027 & 3028.
2006
Principal Investigator: Cyberonics E-20: A Randomized, Parallel-Group Comparison
Treatment with Pharmacotherapy or Adjunctive Vagus Nerve Stimulation therapy for
Pharmacoresistant Partial Seizures: A Large Simple Effectiveness Trial. 2006
Principal Investigator: GlaxoSmithKline LAM100034: A Multicenter, Double-Blind
Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL™
Extended-release Adjunctive Therapy in Subjects with Partial Seizures. 2006
Principal Investigator: GlaxoSmithKline LAM100036: A Multicenter, Double-Blind,
Randomized, Parallel-group Evaluation of LAMICTAL™ Extended-release Adjunctive
Therapy in Patients with Primary Generalized Tonic-Clonic Seizures, 2006
Principal Investigator: Ortho-McNeil CAPSS-368: Long Term, Open-Label Safety
Study of Oral almotriptan malate 12.5 mg in the Treatment of Migraine in Adolescents.
2006
Sub Investigator: GlaxoSmithKline SK&F105517/COR103561: A Randomized,
Double-Blind, Multi-Center Comparing the Effects of carvedilol phosphate Modified
Release Formulation (COREG-MR) with metoprolol succinate (Toprol-XL) on the Lipid
Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients. 2006
Primary Investigator: GlaxoSmithKline LAM30055: A Multicenter, Double-Blind,
Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for
the Treatment of Partial Seizures. 2006
Sub Investigator: GlaxoSmithKline TRX106573: A Study of Combination Product
(sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor
Response or Intolerance to eletriptan. 2006
Principal Investigator: Healthcare Products Development Inc. PRO513: A Multi-
Center, Prospective, Randomized, Double-Blind, Parallel Group, Single-Dose, Placebo-
Controlled Study of the Efficacy and Safety of diclofenac potassium sachet (50mg
diclofenac potassium (K) Powder) Compared to sachet Placebo in Subjects with Acute
Migraine Attacks. 2006
Primary Investigator: Schwarz SP906: A Muiti-Center, Randomized, Double-Blind,
Placebo-Controlled Trial to Assess to Efficacy and Safety of 100mg/day and 300mg/day
lacosamide for Migraine Prophylaxis. 2007
Sub Investigator: Torrey Pines NGX424MIG2001: A Double-Blind, Placebo-
Controlled, Parallel Group, Multi-Center Study to Assess the Safety, Efficacy and
Tolerance of a Single Subcutaneous Dose of Tezampanel in Patients with Acute Migraine.
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 10
2007
Primary Investigator: Pfizer A0081074: A Placebo-Controlled, Rising Dose, Multiple
Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of pregabalin in
Pediatric Patients with Partial Onset Seizures. 2007 (Phase I)
Primary Investigator: Pfizer A0081075: A 12-Month Open-Label Extension Study
Evaluating the Safety and Tolerability of Flexible Doses of pregabalin in Pediatric
Patients with Partial Onset Seizures. 2007
Primary Investigator: Merck 011/MK0974: A Multi-Center, Double-Blind, Placebo
and Active-Controlled, Parallel Group Study to Examine to Compare the Efficacy and
Safety of Oral MK-0974 with Placebo and zolmitriptan for the Acute Treatment of
Migraine With or Without Aura. 2007
Primary Investigator: Merck 012-02/MK0974: A Multi-Center, Double-Blind, Active-
Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral
MK-0974 for the Long-Term Treatment of Acute Migraine With or Without Aura. 2007
Primary Investigator: Abbott M06-818: A Randomized Double-Blind, Placebo-
Controlled, Phase II Dose-Ranging Study of the Safety and Efficacy of ABT-894 in
Adults With Attention Deficit-Hyperactivity Disorder (ADHD). 2007
Primary Investigator: Merck DPA579/024-01: A Multi-Center, Randomized, double-
Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B
(Dosed as coadministered MK-0524A and simvastatin Tablet) vs.atorvastatin in Patients
with Hyperlipidemia. 2007
Sub Investigator: King Pharmaceuticals Research and Development, Inc, K644-07-
3001: A Phase III Open Label Study to Assess Subcutaneous Self Injection with
sumatriptan succinate Using the [Trade name] Auto Injector During a Single Migraine
Attack. 2007
Primary Investigator: PRA International NO1280/NO1281: A Multi-Center, Double-
Blind, Historical Control Randomized Conversion to Monotherapy with Keppra XR for
Treatment of Partial Onset Seizure Study. 2007-Present
Sub Investigator: GlaxoSmithKline TRX109013: A Randomized, Double-blind,
Doubie-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of
TREXIMA (sumatriptan + naproxen sodium) versus butalbital-containing Combination
Medications (BCM) for the Acute Treatment of Migraine when administered during the
Moderate-Severe Pain Phase of the Migraine. 2007-2010
Primary Investigator: NuPathe Inc. NP101-007: The Efficacy and Tolerability of
NP101, a sumatriptan iontophoretic transdermal Patch, in the Treatment of Acute
Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. 2007-2009
Primary Investigator: Pfizer A0081047: A Double-Blind, Randomized, Historical-
Controlled, Multi-Center Efficacy and Safety Study of pregabalin (Lyrica) as
Monotherapy in Patients with Refractory Partial Seizures. 2007-Present
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 14
Primary Investigator: Pfizer 4000801160: An Open-Label Multicenter Extension
Study to Determine Long Term Safety and Efficacy of pregabalin (Lyrica) as
Monotherapy in Patients with Partial Seizures, 2008-Present
Sub Investigator: MAP0004-CL-P301: A Randomized, Double-Blind, Placebo-
Controlled, Parallel Group Study of MAP0004 (Tempo DHE) in Adult Migrainers.
2008-Present
Primary Investigator: Pfizer A2501059: A 10-Week, Double-Blind, Placebo-
Controlled Study to Evaluate the Efficacy and Safety of donepezil hydrochioride
(ARICEPT) in the Treatment of the Cognitive Disfunction Exhibited by Children with
Down Syndrome. 2008-Present
Primary Investigator: Pfizer A2501060: An Open-Label Study to Evaluate the Safety
of donepezil hydrochloride (ARICEPT) For Up To 1 Year In the Treatment of the
Cognitive Disfunction Exhibited by Children with Down Syndrome — Follow-Up to a 10-
Week Double-Blind, Placebo-Controlled Trial. 2008-Present
Sub Investigator: PPD Development, LP Depomed 81-0062: A Phase 3 Multicenter,
Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of
Once-Daily gabapentin extended release (G-ER) Tablets in the Treatment of Patients with
Postherpetic Neuralgia. 2008-Present
Primary Investigator: Quintiles Inc. E2020-G0000-333: Randomized, Double-Blind,
Placebo-Controlled Study of Efficacy and Safety of donepezil hydrochloride in
Preadolescent Children with Attention Impairment Following Cancer Treatment. 2008-
Present
Primary Investigator: Protocol B4Z-MC-LYDO: Maintenance of Response After
Open-Label Treatment with atomoxetine hydrochloride in Adult Outpatients with
Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlied, Randomized
Withdrawal Study. 2008-Present
Primary Investigator: JPI protocol 07-001: A Phase 2a, Open-label, Proof-of-Concept
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal clonazepam in
Adult Subjects with Epileptic Seizures. 2008
Primary Investigator: TXA107979: A Randomized, Multicenter, Placebo-Controlled,
Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product
Containing sumatriptan and naproxen sodium for the Acute Treatment of Migraine in
Adolescents
Primary Investigator: RABGRD3003A Multi-Center, Double-Blind, Parallel-Group
Study to Evaluate Short-Term Safety and Efficacy and Long-term Maintenance of Two
Dose Levels of rabeprazole sodium Delayed-Release Pediatric Bead Formulation in 1- to
1]-Year-Old Pediatric Subjects with Endoscopically Proven GERD.
Primary Investigator: AMDC-104-202: A Multi-Center, Randomized, Double-Blind,
Placebo-Controlled, Single-Dose Efficacy and Safety Study of Staccato® loxapine for
Inhalation in Outpatients with Migraine Headache
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 12
Primary Investigator: NP101-008. An Open-Label Study To Evaluate the Safety of
NP101, a sumatriptan iontophoretic Transdermal Patch, in the Treatment of Acute
Migraine over 12 Months 2009-Present
Primary Investigator: NP101-009. An Open-Label Study To Evaluate the Safety of
WNP101, a sumatriptan iontophoretic Transdermal Patch, in the Treatment of Acute
Migraine over 12 Months. 2009-Present
Primary Investigator: E2020-A001-335 / A2501061. A 10-Week, Double-Blind,
Placebo-Controlled Study to Evaluate the Efficacy and Safety of donepezil hydrochloride
(Aricept®) in the Treatment of the Cognitive Dysfunction Exhibited by Children with
Down Syndrome, Aged 11 to 17
Primary Investigator: E2020-A001-336 (A2501062). Pfizer/Eisai Pediatric Down
Syndrome Study: “A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the
Efficacy and Safety of donepezil hydrochloride (Aricept®) in the Treatment of the
Cognitive Dysfunction Exhibited by Children With Down Syndrome, Aged 6-10”.
Sub-Investigator: ALXA 104-202: A Multi-center, Randomized, Double-Blind, Placebo-
Controlled, Single Dose Efficacy and Safety Study of Staccato Loxapine for Inhalation in
Outpatients with Migraine Headache
Sub-Investigator: Merck082: A Worldwide, Randomized, Double Blindm Placebo-
Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of
Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents. April
2010-Present
Sub-Investigator: Merck086: A Worldwide, Open Label, Clinical Trial to Examine Long
Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of
Migraine With or Without Aura. April 2¢10-Present
Primary Investigator: Otsuka 31-09-268: An Open-label, Muti-Center, Two-Phase,
Sequential Design, Single and Multiple Dose Study to Assess the Safety, Tolerability, and
Pharmacokinetic Profile of an Extended Release Once-weekly Oral Formulation and an
Enteric Coated Extended Release Once-weekly Oral Formulation of Aripiprazole
Administered to Children and Adolescents with Tourette’s Disorder. June 2010 — June
2011. (Phase 1)
Primary Investigator: Otsuka 31-09-265: An Open-label, Muti-Center, Three-Phase,
Sequential Design, Single and Multiple Dose Study to Assess the Safety, Tolerability, and
Pharmacokinetic Profile of an Enteric Coated Once-weekly Oral Formulation of
Aripiprazole Administered to Children and Adolescents with Tourette’s Disorder. October
2010 —June 2011. (Phase 1)
Primary Investigator: Lilly, Protocol HéP-MC-HDAX: Study to Assess the Efficacy and
Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17
in the Treatment of Major Depressive Episodes Associated with Bipolar I Disorder. 2009
—Present. (Phase IV)
Primary Investigator: Johnson & Johnson, RABGRD3004: A Multicenter, Double-
Blind, Randomized, Placebo-Controlled, Parallel-Group, Withdrawal Study to Evaluate
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 13
the Safety and Efficacy of Delayed-Release Rabeprazole in 1- to 1 1-onth-Old Pediatric
Subjects with Symptomatic/Erosive Gastro-esophageal Reflux Disease (GERD). (Phase
TH)
Primary Investigator: Schwarz Biosciences, SP902: A Historical-controlled,
Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of
Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset
Seizures. 2008 — Present. (Phase ITE)
Primary Investigator: Schwarz Biosciences, $P904: A Multicenter, Open-label
Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of
Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures.
2008 — Present. (Phase III)
Sub-Investigator: A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled Study
to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-559, a
Live Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus in Healthy 1 to
<24 Month-Old Children. Protocol No. MI-CP147 2009-Present (Phase II)
Sub-Investigator: MI-CP178: A Phase 1/2a, Randomized, Double-Blind, Placebo-
Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity
and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine
Against Respiratory Syncytial Virus (RSV) and Para-influenza Virus Type 3 (PIV3), in
Healthy 6 to <24 Month-Old Children and in 2 Month-Old Infants 2009-2011 (Phase III)
Primary Investigator: A Long-Term, Open-Label, Safety Study of Eszopiclone in
Children (6 to 11 years) and Adolescents (12 to 17 years) with Attention-
Deficit/Hyperactivity Disorder-Associated Insomnia. Protocol Number 190-247, 2009-
Present (Phase III).
Primary Investigator: A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-
Armed Parallel Group Study to Evaluate the Efficacy of Zohnitriptan 0.5-, 2.5- and 5-mg
Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents. 2010-Present
(Phase IID.
Primary Investigator: Eisai, E2080-G000-303: A Multicenter, Randomized, Controlled,
Open-label Study to Evaluate the Cognitive Development Effects and Safety, and
Pharmacokinetics to Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to less than
4 years of age with Inadequately Controlled Lennox-Gastaut Syndrome. May 2011 —
Present. (Phase Ii)
Primary Investigator: Forest Laboratories, MLN-MD-14: A Multicenter, Randomized,
Double-Blind, Placebo Controlled Withdrawal Study to Evaluate the Safety, Tolerability,
and Efficacy of Milnacipran in Pediatric patients with Primary Fibromyalgia. May 201! ~
Present. (Phase III)
Primary Investigator: Forest Laboratories, MLN-MD-29: A Multicenter, Open-Label,
52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatric
patients with Primary Fibromyalgia. May 2011 — Present. (Phase III)
Primary Investigator: Seaside Therapeutics, 209FX301: A Randomized, Double-Blind,
Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 14
(Arbaclofen) Administered for the Treatment of Social Withdrawal in Adolescents and
Adults with Fragile X Syndrome May 2011 — Present. (Phase TI)
Primary Investigator: Seaside Therapeutics, 209AS208: A Randomized, Double-Blind,
Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209
(Arbaclofen) Administered for the Treatment of Subjects with Autism Spectrum
Disorders. May 2011 — Present. (Phase III)
Revised
May 2011
JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 415
Preview
Filed 12 Ma 25 P1:51 Chris Daniel - District Clerk Harris Coun! CURRICULUM VITAE ED101) 016898557 By: Charlie Tezeno JERRY J. TOMASOVIC, M.D. FRA IS RR IIHR HATES IO HIRT RTE ATTA TIA BRIER IIIT TR TITER TTR TITRA IE ADDRESS: Road Runner Research Management, LLC 525 Oak Centre Drive, Suite 400 San Antonio, Texas 78258 EDUCATION AND TRAINING: Undergraduate: University of Chicago, Chicago, IL, B.S., 1962 Medical School: University of Chicago, Chicago, IL, M.D., 1965 Rotating Internship - USAF Hospital Andrews, Andrews AFB, 1965-66 Pediatric Residency - US Naval Hospital Bethesda, Bethesda, 1966-68 Pediatric Neurology Fellowship - University of Colorado Medical Center, ae Denver, CO, 1972-75 BOARD CERTIFICATIONS/LICENSURES: Diplomate American Board of Pediatrics, 1970 Diplomate American Board of Psychiatry and Neurology with Special Competence in Child Neurology, 1978 Association of Professional Sleep Societies, July 1989 Professional Licensure: Texas, February 1985 No. G7730 PRACTICE EXPERIENCE: Owner, President of Road Runner Research Management, LLC, Jan. 2006-Present. Owner, President, and Medical Director, Road Runner Research, Ltd., October 2005- Present. Owner, President, and Medical Director, Texas Association of Pediatric Neurology, Inc., June 2000- Present. Medical Director, Spasticity Clinic, S.W. Texas Methodist Hospital, San Antonio, TX, 1997-Present. Consultant, Pediatric Neurology, Movement Disorders Clinic, Warm Springs Hospital, San Antonio, TX, 1997-2002, Private Practice, Adult and Child Neurology, San Antonio, TX, 1985-Present. Medical Director, Sleep Diagnostics Services Inc, San Antonio, TX, 1992-2009 One Oak Hills Place, 1901 Babcock Rd, suite 201, SA, TX 78229 JERRY J. TOMASOVIC, MD - CURRICULUM VITAE Neurological Program Consultant, Laurel Ridge Hospital, San Antonio, TX, 1992-2000 Co-Medical Director, Sleep/Wake Disorders Center of South Texas, San Antonio, TX. 1988-1992, Teaching clinic monthly at Wilford Hall USAF Medical Center, Lackland AFB, TX, 1988-1993. Co-Medical Director, Electroneurodiagnostic Laboratory of San Antonio, TX, 1987-1994 Co-Unit Medical Director, Neuropsychiatric Inpatient Unit, Laurel Ridge Hospital, San Antonio, TX, March 1988-1991, Co-Medical Director, Neurobehavioral Evaluation Team (NET), San Antonio, TX, 1989- 1991, Associate Professor of Pediatrics, University of Texas Health Science Center at San Antonio, TX, 1985-1986 Chairman, Department of Neurology and Program Director, USAF Neurology Residency Program, Wilford Hall USAF Medical Center, Lackland AFB, TX, 1979-1985. Staff Child Neurologist, Department of Pediatrics, Wilford Hall USAF Medical Center, Lackland AFB, TX, 1977-1979. Child Neurologist, Assistant Chairman, Department of Pediatrics, USAF Hospital Travis, Travis AFB, CA, 1975-1977. Staff Pediatrician, USAF Hospital Wiesbaden, Germany, 1968-1972 (Assistant Chief, 1969-1972) ACADEMIC APPOINTMENTS: Clinical Professor of Neurology, University of Texas Health Science Center at San Antonio, TX, September 2003-Present. Clinical Professor of Pediatrics, University of Texas Health Science Center at San Antonio, TX, September 1994-Sept 2003. Clinical Associate Professor of Pediatrics, University of Texas Health Science Center at San Antonio, TX, 1978-1985 and 1986-1994. Clinical Associate Professor of Neurology, University of Texas Health Science Center at San Antonio, TX, 1980-1985. Associate Scientist (Adjunct), Southwest Foundation for Biomedical Research, San Antonio, TX, 1986-1989. Assistant Clinical Professor of Pediatrics, University of California, Davis, CA, 1975-1977. Clinical Associate Professor of Neurology, Uniformed Service of the Health Sciences, JERRY J. TOMASOVIC, MD - CURRICULUM VITAE School of Medicine, Bethesda, MD, 1980-1985. MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS: Member, American Academy of Neurology, 1974-present. Member, Child Neurology Society, 1974-present. Member, American Sleep Disorders Association, 1986-present. Member, Bexar County Medical Society, 1985-present. Member, Texas Medical Association, 1985-present. Member, American Medical Association, 1989-present. Member, American Epilepsy Society, 1977-1999. Member, American Academy of Child & Adolescent Psychiatry, 1992-1999. Member, San Antonio Pediatric Society, 1985-1990. PROFESSIONAL HONORS/EXECUTIVE POSITIONS HELD: Legion of Merit, United States Air Force, 1977-1985. Professional and Community Advisory Council, Epilepsy Foundation of America, San Antonio, TX, 1992-Present. Chairman, Department of Neurology and Program Director, USAF Neurology Residency Program, Wilford Hall USAF Medical Center, Lackland AFB, TX, 1979-1985. Military Consultant to the Surgeon General for Adult and Child Neurology, 1980-1985. Chairman, Committee on Neurology and Government Services, American Academy of Neurology, 1983-1984. President, Uniformed Services of Neurologists, 1984-1985. Fellow, American Academy of Neurology, 1985. Voted Best Doctors in America 2011-Present. Texas Super Doctors, a special section in Texas Monthly, featuring 5% of Texas doctors, 2008-Present One of America’s Most Compassionate Doctors, Patients’ Choice Rated and Awarded by Patients, 2008-Present PUBLISHED ARTICLES, SPEECHES, and LECTURES: a. J.J. Tomasovic, T. Sabo: Improvement of Intractable Headache in Adolescents Females after Craniocervical Injections of BTX-A (Allergan), Headache, Vol 43, No.5, May2003, pp.579-580 J.J. Tomasovic, D.E. Solomon, D.H, Solomon: Chapter 11: Neurologic Consultation. Clinical Anesthesia Practice, W.B. Saunders Company, Philadelphia, PA, 1994, pp. 152-169. JERRY J. TOMASOVIC, MD - CURRICULUM VITAE J.J. Tomasovic, Neurobiology of Aggression, proceeding from 9th National Conference of Child Psychiatry, sponsored by Mexican Association for Child Psychiatry, Guanajuato, Mexico, November 1992. L.A. Stone, J.J. Tomasovic, T.A. Martin, M.B. Zuelzer, E.C. Gooze: Episodic Dyscontrol, Disinhibition, Explosive Personality, and Intermittent Explosive Disorders, proceedings from 39th Annual Meeting of American Academy of Child and Adolescent Psychiatry, Washington, D.C., October 1992, W.White, J. Mumma, J.J. Tomasovic: Congenital Oculomotor Nerve Palsy, Cerebellar Hypoplasia, and Facial Capillary Hemangioma, American Journal of Ophthalmology, Vol. 113, No. 5, May 15, 1992, pp. 497-500. J.J. Tomasovic: Sleep Disorders, The Treatment of Psychiatric Disorders, Revised for the DSM3R, Wm. H. Reid Ed., Chapter 22, 1989, pp. 296-310. M. Brunsvold, J.J. Tomasovic, D. Ruemping: The Measured Effects of Phenytoin Withdrawal on Gingival Hyperplasia in Children, Journal of Dentistry for Children, November-December 1985, pp. 417-421. h. B. Ryan, R. Bell, D. Null, J.J. Tomasovic, Dryer: Study of the Effects of Sleep State Upon Anterior Cerebral Artery Flow Characteristics in Neonates. Abstract presented in San Francisco, CA, 1982. S.A, McGuire, N. Ackerman, J.J. Tomasovic: Hereditary Continuous Muscle Fiber Activity. Arch Neurology, Vol. 41, April 1984. S.A. McGuire, J.J. Tomasovic, E.A. Stevens: Improvement With Corticotropin of Relapsing CNS Sarcoidosis During Prednisone Therapy. Military Medicine, Vol. 149, No. 5, May 1983. R.A. DeLemos, D. Null, J.J. Tomasovic: The Role of Postnatal Factors in the Pathogenesis of Subependymal and Intracranial Hemorrhage in the Premature Infant. Syllabus of the Perinatal Intracranial Hemorrhage Conference Washington, D.C., December 11-13, 1980. JL. Liston, J.J. Tomasovic: Early Diagnosis and Management of Cerebritis in a Child. Pediatrics, 1980, 65:484. J.G. Marks, Jr., J.J. Tomasovic: Linear Nevus Sebaceous Syndrome. Journal of the American Academy of Dermatology, Vol. 2, No.1, 1980, pp. 31-32. R.A. DeLemos, J.J. Tomasovie: Effects of Positive Pressure Ventilation on Cerebral Blood flow in the Newborn Infant. Symposium on the respiratory system. Clinics in Perinatology, Vol. 5, No. 2, September 1978, pp. 395-409. J.J, Tomasovic, G. Nellhaus, P.G. Moe: The Bobble-Head Doll Syndrome: An Early Sign of Hydrocephalus. Two new cases and a review of the literature. JERRY J. TOMASOVIC, MD - CURRICULUM VITAE Developmental Med and Child Neurology, Vol. 17, No. 6, December 1975, pp. 777-183. 10. REVIEWS: a, Distal Jugular Venous Cannulation During Extracorporeal Membrane Oxygenation in Neonates by Ernesto S. Gangitan, M.D., et. al. for Pediatrics, October 1991. Neonatal Neurology by Gerald M. Fenichel, P. 270, New York Churchill- Livingston, 1980 for Arch Neurology, vol. 38, June 1981. 1h. HOSPITAL PRIVILEGES AND PROFESSIONAL STAFF, SAN ANTONIO, TEXAS a Active Staff: S.W. Texas Methodist Children’s Hospital North Central Baptist Hospital Santa Rosa Children’s Hospital Laurel Ridge Hospital Consulting Staff: Baptist Memorial Hospital System Covenant Hospital Mission Road Developmental Center Northeast Methodist Hospital Santa Rosa Hospital System Sid Peterson Memorial Hospital, Kerrville, TX. Vencor Hospital Warm Springs Rehabilitation Hospital West Texas Rehabilitation Center, San Angelo, TX JERRY J. TOMASOVIC, MD - CURRICULUM VITAE CLINICAL RESEARCH EXPERIENCE: Principal Investigator: Protocol for a Multicenter Long Term Study to Maximize Migraine Relief with 311C90 Sub-Investigator: A Multicenter, Double-Blind, Randomized Placebo-Controlled. Parallel Group Study of the Efficacy and Safety of Oral xxxxxx in Adolescent Subjects Ages 12-17 Years with Acute Migraine Principal Investigator: A Multicenter, Randomized, Open-Label, Comparative Study of the Safety, Toleration and Efficacy of Oral xxxxxx FOR long Term Treatment of Subjects with Acute Migraine Principal Investigator: Safety and Efficacy of xxxxx in the Treatment of Pediatric Patients with Partial Seizures Principal Investigator: An Open-Label Extension Study of xxxx in the Treatment of Pediatric Patients with Partial Seizures Principal Investigator: A Double-Blind, Placebo-Controlied, Parallel Group Study to Evaluate Three Dose Levels (Smg, 10mg, 20 mg) of xxxxxxxxNasal Spray in the Acute Treatment of a Single Migraine Attack in Adolescent Migraineurs (12-17 years of age) Sub-Investigator: An open-Label Study to Evaluate the Long Term Efficacy, Safety and Tolerability of xxxxxxx Nasal Spray xxxxxxx in an Adolescent Migraine Population Principal Investigator: Almirall 638-CNS-0059-015 - A Randomized, Doubie-Blind, Placebo-Controlled Study of Oral almotriptan in the Acute Treatment of Migraine in Adolescents Principal Investigator: UCB Pharma RPCE97L2601 - A Multicenter, Open Label, Long-Tterm, Follow-Up Study of the Safety and Efficacy of levetiracetam in Children with Epilepsy Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Evaluation of xxxxx (311090, XXXX) Efficacy at Early Time Points in the Acute Treatment of Migraine Headaches, Efficacy in Recurrence of Migraine Headaches Principal Investigator: A Double-Blind, Randomized Trial of Two Dose Ranges of xxxxxxxx and Placebo in the Prophylactic Treatment of Migraine Sub-Investigator: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial and an Open Label Long-term Tolerability Trial of x200xx (xxxxxx) for the Acute Treatment of Migraine Headaches in Adolescent Subjects Sub-hnvestigator: "An Open-Label Study to Evaluate the Long Term Efficacy, Safety and Tolerability of (GR43175C) in an Adolescent Migraine Population," Principal Investigator: MerckMAX564: A Multicenter, Double-Blind, Randomized, the Efficacy and Tolerability of Rizatriptan 10 mg Tablet for the Treatment of Menstrual JERRY J. TOMASOVIC, MD - CURRICULUM VITAE Migraines Principal Investigator: Merck MK-0462-074-00 /MAX573: A Randomized, Double-Blind, Placebo —Controlled Study to Evaluate the Elimination of Migraine Associated Nausea in Migraine Patients Treated with rizatriptan orally Disintegrating Tablet (ODT) Primary Investigator; Cephalon Eclipse MOO-190: A Compliance Packaging and Safety Assessment of Two Packaging Formats and Dosing Regimens of Gabitril in Subjects with Partial-Onset Seizures. January 2001-September2001. Primary Investigator: Shire Pharmaceutical SLI381-305: An Open-Label, Multicenter Study to Assess Tolerability, Effectiveness and Quality of Life Associated with The Use of Adderall XR in Children with Attention Deficit Hyperactivity Disorder in a Community Practice Setting. August 2001 -January 2002. Sub-Investigator: UCB Pharma RPCE9862502/N159: Evaluation of the Efficacy and Tolerability of Levetiracetam Add-on Treatment in Refractory Pediatric Patients with Partial- Onset Seizures: A 28-week Double-Blind, Placebo-Controlled Multicenter Trial. August 2001-March 2003. Sub-Investigator: Allergan Botox 01 (Investigator Initiated, Pilot Study) B -Botulinum Toxin A for Migraine Prophylaxis in an Adolescent Population. September 2001-March 2003. Primary Investigator: GlaxoSmithKline SUM40301: An Open-Label Evaluation of Patient Satisfaction with Imitrex tablets 100 mg, Administered at the First Sign of Pain for up to Three Migraine in Patients Who are Not Satisfied with Their Current Triptan Therapy. November 2001-June 2003 Primary Investigator: GlaxoSmithKline LAM40013: A Multicenter Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients with Epilepsy. January 2002-March 2003. Primary Investigator: Abbott M02-552: A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Safety and Efficacy of Depakote in Treatment of Partial Seizures in. Children. Nov. 2003 Principal Investigator: Shire SPD433-401 Cabatrol SPEQT (Safety, Preference, Effectiveness, and Tolerability) Trial, A Multicenter, Open Label, Phase IV Study to Assess the Tolerability, Safety and Effectiveness of Switching from Carbamazepine Immediate Release and Liquid Formulations to Carbatrol Extended Release Capsules in Epilepsy Subjects Within a Community Based Population. June 2003 Sub-Investigator; Glaxo Wellcome LAM40097: A Multi-Center, Double-Bind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subject with Primary Generalized Tonic-Clonic Seizures. March 2000-2004 Sub-Investigator: UCB Pharma RPCE97L2601/N157: A Multicenter, Open-Label, Long-Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam (ucb L059) in Children with Epilepsy. August 2001-May 21,2004 JERRY J. FOMASOVIC, MD - CURRICULUM VITAE Primary Investigator: GlaxoSmith Kline RM2004/00208/00: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single Attack Evaluation of the Efficacy and Tolerability of Trexima (sumatriptan 85 mg/naproxen sodium 500 mg) tablets versus Placebo When Administered During the Mild Pain Phase of a Migraine. December 2004 Sub- Investigator: OrthoMcNeil CAPSS-122: A Comparison of the Efficacy and Safety of topiramate Versus Placebo for the Prophylaxis of Migraine in Pediatric Subjects. Completed March 2004. Primary Investigator: Ortho McNeil Protocol 638-CNS-0059-015: A Randomized, Double- Blind, Placebo-Controlled Study of Oral almotriptan 6.25 mg, 12.5 mg and 25 mg in the Acute Treatment of Migraine in Adolescents. April 2004 Primary Investigator: Novartis CRTI47B US36 & Extension Portion of Study: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Trileptal as Prophylactic Therapy in Outpatients Suffering from Migraine Headaches. Completed May 2004 Primary Investigator: GlaxoSmithKline CXA20008: A Multicenter, Randomized, Double- Blind, Single-Dose, Parallel Group Pilot Study to Assess the Safety and Efficacy of the Cox-2 Inhibitor versus Placebo and Naproxen Sodium versus Placebo in the Treatment of Acute Migraine. 2003-May 2004 Primary Investigator: GlaxoSmithKline SUM30047: A Randomized, Double Blind, Placebo- Controlled, Paralle] Group, Single Attack Study to Evaluate the Onset of Efficacy of a New Formulation of sumatriptan Tablets in the Acute Treatment of Migraine. 2003-2004 Primary Investigator: Astra Zeneca D1221C0005: A Multicenter, Double-Blind, Randomized, Placebo Controlled, 2way Crossover Study with a Single-Blind Placebo-challenge to Evaluate the Efficacy and Safety of zolmitriptan Smg Nasal Spray in the treatment of Acute Migraine Headache in Adolescents . 2004 Primary Investigator: GlaxoSmithKline LAM40097: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation of lamotrigine Adjunctive Therapy in Subject with Primary Generalized Tonic-Clonic Seizures. 2004 Primary Investigator: UCB Pharma RPCE97L.2601: A Multicenter, Open-Label, Long-Term, Follow-Up Study of the Safety and Efficacy of levetiracetam in Children with Epilepsy. 2004. Primary Investigator: Astra Zeneca D1221C0005: A Multicenter, Double-Blind, Randomized, Placebo Controlled, 2way Crossover Study with a Single-Blind Placebo-Challenge to Evaluate the Efficacy and Safety of zolmitriptan Smg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents. 2004 Primary Investigator: Protocol 065: A Multicenter, Double-Blind, Randomized, Parallel. Placebo-Controlled study to examine the Efficacy of rizatriptan 10 mg Tablet administered early during a Migraine Attack while the Pain is Mild. April 2005 Primary Investigator: Protocol 066-00/MAX550: A Multicenter, Double-Blind, Randomized. Parallel, Placebo-Controlled Study to Examine the Efficacy of rizatriptan JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 10mg Tablet administered Early during a Migraine Attack While the Pain is Mild. Primary Investigator: MT400-302: A Double-Blind, Multicenter, Randomized, Placebo-Controlled study to evaluate the Safety and Efficacy of the Combination of sumatriptan succinate and naproxen sodium in the Acute Treatment of Migraine Headaches. 2005 Primary Investigator: GSK Lam40124: An Assessment of Behavioral Changes Associated with jamotrigine and levetiracetam in Patients with Epilepsy. June 2003 Primary Investigator: Almirall 638-CNS-0059-015: A Randomized, Double-Blind Placebo- Controlled Study of Oral almotriptan in the Acute Treatment of Migraine in Adolescents. Principal Investigator: Cephalon 3027: A Randomized, Double-Blind, Placebo- Controlled, Parallel Group Study to Assess the Efficacy and Safety of Provigil Treatment in Children and Adolescents with Excessive Sleepiness Associated Narcolepsy. 2005 Principal Investigator: Abbott M02-488: The Safety and Efficacy of divalproex sodium Extended-Release Tablets in Migraine Prophylaxis in Adolescents. 2006 Principal Investigator: Abbott M02-554: Extension Study to Above Protocol M02-488 2006 Principal Investigator: Abbott M04-714: An Open Label Multicenter Study of Long- Term Safety of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children, 2006 Principal Investigator: Ortho-McNeil CAPSS-316: Efficacy and Safety of Axert versus Placebo for the Acute Treatment of Migraine Headaches. Principal Investigator: Cephalon 3028: A Randomized, Double-Blind, Placebo- Controlled, Parallel Group Study to Assess the Efficacy and Safety of Provigil Treatment in Children and Adolescents with Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome. 2005 Principal Investigator: Schwarz Trial Number SP754: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Paralle! Group Trial to Investigate the Efficacy and Safety of SPM927 (400 AND 600mg/DAY) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization. 2005 Principal Investigator: GlaxoSmithKlineTRX 103632: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for Trexima™ (sumatriptan 85mg/naproxen sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks, 2005 Primary Investigator: Merck 074-00/MAX573: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Treated with rizatriptan Orally Disintegrating Tablet (ODT). 2005 Principal Investigator: Schwarz Trial Number SP756: An Open-Label Extension Trial to Determine Safety and Efficacy of Long-Term Oral SPM 927 in Patients with Partial JERRY J. TOMASOVIC, MD - CURRICULUM VITAE Seizures. 2005 Principal Investigator: OrthoMeNeil CAPSS 334 Efficacy of AXERT® (almotriptan malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy with TOPAMAX® (topiramate). 2005 Principal Investigator: Cephalon 3029 - Extension Study to Protocols 3027 & 3028. 2006 Principal Investigator: Cyberonics E-20: A Randomized, Parallel-Group Comparison Treatment with Pharmacotherapy or Adjunctive Vagus Nerve Stimulation therapy for Pharmacoresistant Partial Seizures: A Large Simple Effectiveness Trial. 2006 Principal Investigator: GlaxoSmithKline LAM100034: A Multicenter, Double-Blind Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL™ Extended-release Adjunctive Therapy in Subjects with Partial Seizures. 2006 Principal Investigator: GlaxoSmithKline LAM100036: A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL™ Extended-release Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures, 2006 Principal Investigator: Ortho-McNeil CAPSS-368: Long Term, Open-Label Safety Study of Oral almotriptan malate 12.5 mg in the Treatment of Migraine in Adolescents. 2006 Sub Investigator: GlaxoSmithKline SK&F105517/COR103561: A Randomized, Double-Blind, Multi-Center Comparing the Effects of carvedilol phosphate Modified Release Formulation (COREG-MR) with metoprolol succinate (Toprol-XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients. 2006 Primary Investigator: GlaxoSmithKline LAM30055: A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures. 2006 Sub Investigator: GlaxoSmithKline TRX106573: A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to eletriptan. 2006 Principal Investigator: Healthcare Products Development Inc. PRO513: A Multi- Center, Prospective, Randomized, Double-Blind, Parallel Group, Single-Dose, Placebo- Controlled Study of the Efficacy and Safety of diclofenac potassium sachet (50mg diclofenac potassium (K) Powder) Compared to sachet Placebo in Subjects with Acute Migraine Attacks. 2006 Primary Investigator: Schwarz SP906: A Muiti-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Assess to Efficacy and Safety of 100mg/day and 300mg/day lacosamide for Migraine Prophylaxis. 2007 Sub Investigator: Torrey Pines NGX424MIG2001: A Double-Blind, Placebo- Controlled, Parallel Group, Multi-Center Study to Assess the Safety, Efficacy and Tolerance of a Single Subcutaneous Dose of Tezampanel in Patients with Acute Migraine. JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 10 2007 Primary Investigator: Pfizer A0081074: A Placebo-Controlled, Rising Dose, Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of pregabalin in Pediatric Patients with Partial Onset Seizures. 2007 (Phase I) Primary Investigator: Pfizer A0081075: A 12-Month Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of pregabalin in Pediatric Patients with Partial Onset Seizures. 2007 Primary Investigator: Merck 011/MK0974: A Multi-Center, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Examine to Compare the Efficacy and Safety of Oral MK-0974 with Placebo and zolmitriptan for the Acute Treatment of Migraine With or Without Aura. 2007 Primary Investigator: Merck 012-02/MK0974: A Multi-Center, Double-Blind, Active- Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long-Term Treatment of Acute Migraine With or Without Aura. 2007 Primary Investigator: Abbott M06-818: A Randomized Double-Blind, Placebo- Controlled, Phase II Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD). 2007 Primary Investigator: Merck DPA579/024-01: A Multi-Center, Randomized, double- Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (Dosed as coadministered MK-0524A and simvastatin Tablet) vs.atorvastatin in Patients with Hyperlipidemia. 2007 Sub Investigator: King Pharmaceuticals Research and Development, Inc, K644-07- 3001: A Phase III Open Label Study to Assess Subcutaneous Self Injection with sumatriptan succinate Using the [Trade name] Auto Injector During a Single Migraine Attack. 2007 Primary Investigator: PRA International NO1280/NO1281: A Multi-Center, Double- Blind, Historical Control Randomized Conversion to Monotherapy with Keppra XR for Treatment of Partial Onset Seizure Study. 2007-Present Sub Investigator: GlaxoSmithKline TRX109013: A Randomized, Double-blind, Doubie-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMA (sumatriptan + naproxen sodium) versus butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine. 2007-2010 Primary Investigator: NuPathe Inc. NP101-007: The Efficacy and Tolerability of NP101, a sumatriptan iontophoretic transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. 2007-2009 Primary Investigator: Pfizer A0081047: A Double-Blind, Randomized, Historical- Controlled, Multi-Center Efficacy and Safety Study of pregabalin (Lyrica) as Monotherapy in Patients with Refractory Partial Seizures. 2007-Present JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 14 Primary Investigator: Pfizer 4000801160: An Open-Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures, 2008-Present Sub Investigator: MAP0004-CL-P301: A Randomized, Double-Blind, Placebo- Controlled, Parallel Group Study of MAP0004 (Tempo DHE) in Adult Migrainers. 2008-Present Primary Investigator: Pfizer A2501059: A 10-Week, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of donepezil hydrochioride (ARICEPT) in the Treatment of the Cognitive Disfunction Exhibited by Children with Down Syndrome. 2008-Present Primary Investigator: Pfizer A2501060: An Open-Label Study to Evaluate the Safety of donepezil hydrochloride (ARICEPT) For Up To 1 Year In the Treatment of the Cognitive Disfunction Exhibited by Children with Down Syndrome — Follow-Up to a 10- Week Double-Blind, Placebo-Controlled Trial. 2008-Present Sub Investigator: PPD Development, LP Depomed 81-0062: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Once-Daily gabapentin extended release (G-ER) Tablets in the Treatment of Patients with Postherpetic Neuralgia. 2008-Present Primary Investigator: Quintiles Inc. E2020-G0000-333: Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of donepezil hydrochloride in Preadolescent Children with Attention Impairment Following Cancer Treatment. 2008- Present Primary Investigator: Protocol B4Z-MC-LYDO: Maintenance of Response After Open-Label Treatment with atomoxetine hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlied, Randomized Withdrawal Study. 2008-Present Primary Investigator: JPI protocol 07-001: A Phase 2a, Open-label, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal clonazepam in Adult Subjects with Epileptic Seizures. 2008 Primary Investigator: TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing sumatriptan and naproxen sodium for the Acute Treatment of Migraine in Adolescents Primary Investigator: RABGRD3003A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-Term Safety and Efficacy and Long-term Maintenance of Two Dose Levels of rabeprazole sodium Delayed-Release Pediatric Bead Formulation in 1- to 1]-Year-Old Pediatric Subjects with Endoscopically Proven GERD. Primary Investigator: AMDC-104-202: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Efficacy and Safety Study of Staccato® loxapine for Inhalation in Outpatients with Migraine Headache JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 12 Primary Investigator: NP101-008. An Open-Label Study To Evaluate the Safety of NP101, a sumatriptan iontophoretic Transdermal Patch, in the Treatment of Acute Migraine over 12 Months 2009-Present Primary Investigator: NP101-009. An Open-Label Study To Evaluate the Safety of WNP101, a sumatriptan iontophoretic Transdermal Patch, in the Treatment of Acute Migraine over 12 Months. 2009-Present Primary Investigator: E2020-A001-335 / A2501061. A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of donepezil hydrochloride (Aricept®) in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down Syndrome, Aged 11 to 17 Primary Investigator: E2020-A001-336 (A2501062). Pfizer/Eisai Pediatric Down Syndrome Study: “A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of donepezil hydrochloride (Aricept®) in the Treatment of the Cognitive Dysfunction Exhibited by Children With Down Syndrome, Aged 6-10”. Sub-Investigator: ALXA 104-202: A Multi-center, Randomized, Double-Blind, Placebo- Controlled, Single Dose Efficacy and Safety Study of Staccato Loxapine for Inhalation in Outpatients with Migraine Headache Sub-Investigator: Merck082: A Worldwide, Randomized, Double Blindm Placebo- Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents. April 2010-Present Sub-Investigator: Merck086: A Worldwide, Open Label, Clinical Trial to Examine Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura. April 2¢10-Present Primary Investigator: Otsuka 31-09-268: An Open-label, Muti-Center, Two-Phase, Sequential Design, Single and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of an Extended Release Once-weekly Oral Formulation and an Enteric Coated Extended Release Once-weekly Oral Formulation of Aripiprazole Administered to Children and Adolescents with Tourette’s Disorder. June 2010 — June 2011. (Phase 1) Primary Investigator: Otsuka 31-09-265: An Open-label, Muti-Center, Three-Phase, Sequential Design, Single and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of an Enteric Coated Once-weekly Oral Formulation of Aripiprazole Administered to Children and Adolescents with Tourette’s Disorder. October 2010 —June 2011. (Phase 1) Primary Investigator: Lilly, Protocol HéP-MC-HDAX: Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated with Bipolar I Disorder. 2009 —Present. (Phase IV) Primary Investigator: Johnson & Johnson, RABGRD3004: A Multicenter, Double- Blind, Randomized, Placebo-Controlled, Parallel-Group, Withdrawal Study to Evaluate JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 13 the Safety and Efficacy of Delayed-Release Rabeprazole in 1- to 1 1-onth-Old Pediatric Subjects with Symptomatic/Erosive Gastro-esophageal Reflux Disease (GERD). (Phase TH) Primary Investigator: Schwarz Biosciences, SP902: A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures. 2008 — Present. (Phase ITE) Primary Investigator: Schwarz Biosciences, $P904: A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures. 2008 — Present. (Phase III) Sub-Investigator: A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-559, a Live Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus in Healthy 1 to <24 Month-Old Children. Protocol No. MI-CP147 2009-Present (Phase II) Sub-Investigator: MI-CP178: A Phase 1/2a, Randomized, Double-Blind, Placebo- Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Para-influenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-Old Children and in 2 Month-Old Infants 2009-2011 (Phase III) Primary Investigator: A Long-Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 years) and Adolescents (12 to 17 years) with Attention- Deficit/Hyperactivity Disorder-Associated Insomnia. Protocol Number 190-247, 2009- Present (Phase III). Primary Investigator: A Multicenter, Double-blind, Randomized, Placebo-controlled, 4- Armed Parallel Group Study to Evaluate the Efficacy of Zohnitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents. 2010-Present (Phase IID. Primary Investigator: Eisai, E2080-G000-303: A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics to Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to less than 4 years of age with Inadequately Controlled Lennox-Gastaut Syndrome. May 2011 — Present. (Phase Ii) Primary Investigator: Forest Laboratories, MLN-MD-14: A Multicenter, Randomized, Double-Blind, Placebo Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Pediatric patients with Primary Fibromyalgia. May 201! ~ Present. (Phase III) Primary Investigator: Forest Laboratories, MLN-MD-29: A Multicenter, Open-Label, 52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatric patients with Primary Fibromyalgia. May 2011 — Present. (Phase III) Primary Investigator: Seaside Therapeutics, 209FX301: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 14 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Adolescents and Adults with Fragile X Syndrome May 2011 — Present. (Phase TI) Primary Investigator: Seaside Therapeutics, 209AS208: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Subjects with Autism Spectrum Disorders. May 2011 — Present. (Phase III) Revised May 2011 JERRY J. TOMASOVIC, MD - CURRICULUM VITAE 415